Show simple item record

dc.contributor.authorReid, Joanne
dc.contributor.authorNoble, Helen R
dc.contributor.authorAdamson, Gary
dc.contributor.authorDavenport, Andrew
dc.contributor.authorFarrington, Ken
dc.contributor.authorFouque, Denis
dc.contributor.authorKalantar-Zadeh, Kamyar
dc.contributor.authorMallett, John
dc.contributor.authorMcKeaveney, C
dc.contributor.authorPorter, S
dc.contributor.authorSeres, David S
dc.contributor.authorShields, Joanne
dc.contributor.authorSlee, Adrian
dc.contributor.authorWitham, Miles D
dc.contributor.authorMaxwell, Alexander P
dc.date.accessioned2019-07-17T00:07:20Z
dc.date.available2019-07-17T00:07:20Z
dc.date.issued2018-02-13
dc.identifier.citationReid , J , Noble , H R , Adamson , G , Davenport , A , Farrington , K , Fouque , D , Kalantar-Zadeh , K , Mallett , J , McKeaveney , C , Porter , S , Seres , D S , Shields , J , Slee , A , Witham , M D & Maxwell , A P 2018 , ' Establishing a clinical phenotype for cachexia in end stage kidney disease - study protocol ' , BMC Nephrology , vol. 19 , no. 1 , 38 , pp. 38 . https://doi.org/10.1186/s12882-018-0819-3
dc.identifier.issn1471-2369
dc.identifier.otherPURE: 13704150
dc.identifier.otherPURE UUID: b7bf3778-2082-42ff-9ade-fb6ecd3d3016
dc.identifier.otherPubMed: 29439674
dc.identifier.otherPubMedCentral: PMC5812213
dc.identifier.otherScopus: 85041997229
dc.identifier.urihttp://hdl.handle.net/2299/21436
dc.description.abstractBACKGROUND: Surveys using traditional measures of nutritional status indicate that muscle wasting is common among persons with end-stage kidney disease (ESKD). Up to 75% of adults undergoing maintenance dialysis show some evidence of muscle wasting. ESKD is associated with an increase in inflammatory cytokines and can result in cachexia, with the loss of muscle and fat stores. At present, only limited data are available on the classification of wasting experienced by persons with ESKD. Individuals with ESKD often exhibit symptoms of anorexia, loss of lean muscle mass and altered energy expenditure. These symptoms are consistent with the syndrome of cachexia observed in other chronic diseases, such as cancer, heart failure, and acquired immune deficiency syndrome. While definitions of cachexia have been developed for some diseases, such as cardiac failure and cancer, no specific cachexia definition has been established for chronic kidney disease. The importance of developing a definition of cachexia in a population with ESKD is underscored by the negative impact that symptoms of cachexia have on quality of life and the association of cachexia with a substantially increased risk of premature mortality. The aim of this study is to determine the clinical phenotype of cachexia specific to individuals with ESKD. METHODS: A longitudinal study which will recruit adult patients with ESKD receiving haemodialysis attending a Regional Nephrology Unit within the United Kingdom. Patients will be followed 2 monthly over 12 months and measurements of weight; lean muscle mass (bioelectrical impedance, mid upper arm muscle circumference and tricep skin fold thickness); muscle strength (hand held dynamometer), fatigue, anorexia and quality of life collected. We will determine if they experience (and to what degree) the known characteristics associated with cachexia. DISCUSSION: Cachexia is a debilitating condition associated with an extremely poor outcome. Definitions of cachexia in chronic illnesses are required to reflect specific nuances associated with each disease. These discrete cachexia definitions help with the precision of research and the subsequent clinical interventions to improve outcomes for patients suffering from cachexia. The absence of a definition for cachexia in an ESKD population makes it particularly difficult to study the incidence of cachexia or potential treatments, as there are no standardised inclusion criteria for patients with ESKD who have cachexia. Outcomes from this study will provide much needed data to inform development and testing of potential treatment modalities, aimed at enhancing current clinical practice, policy and education.en
dc.language.isoeng
dc.relation.ispartofBMC Nephrology
dc.subjectCachexia
dc.subjectDefinition
dc.subjectEnd-stage kidney disease
dc.subjectLongitudinal
dc.subjectPhenotype
dc.subjectNephrology
dc.titleEstablishing a clinical phenotype for cachexia in end stage kidney disease - study protocolen
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85041997229&partnerID=8YFLogxK
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1186/s12882-018-0819-3
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record